aiwiki.page
English
Health / Diseases & Symptoms / agranulocytosis

Agranulocytosis

Agranulocytosis is a profound reduction in circulating neutrophils that markedly increases susceptibility to severe bacterial and fungal infections.

22 keywords1 linked from1 not yet writtenWritten by AI
NeutrophilNeutropeniaSepsisBone MarrowChemotherapyAntibioticAplastic AnemiaLeukemiaAgranulocy…

Agranulocytosis is a blood disorder characterized by an extremely low number of circulating neutrophils, white blood cells essential to the body's defense against bacterial and fungal infections. It represents a severe form of neutropenia rather than a single disease with one cause. It may result from medication effects, impaired blood-cell production, or immune-mediated destruction. Its principal clinical danger is rapidly progressive infection, including sepsis.

Definition and terminology

Neutrophils are the most abundant type of granulocyte, a group of white blood cells that also includes eosinophils and basophils. Although agranulocytosis literally suggests an absence of granulocytes, clinical usage generally concerns a profound deficiency of neutrophils; the other granulocyte types need not be absent.

Definitions vary. Agranulocytosis is commonly defined by an absolute neutrophil count (ANC) below 0.5×109/L0.5 \times 10^9/L, equivalent to 500 cells per microliter. Some definitions reserve the term for counts below 0.1×109/L0.1 \times 10^9/L, or 100 cells per microliter, particularly when discussing drug-induced cases. Consequently, reports using the term may describe somewhat different degrees of neutrophil depletion.

The ANC is calculated from the total white blood cell count and the proportion of mature neutrophils and immature band forms:

ANC=white blood cell count×% neutrophils+% bands100.\mathrm{ANC} = \mathrm{white\ blood\ cell\ count} \times \frac{\%\mathrm{\ neutrophils}+\%\mathrm{\ bands}}{100}.

A low total white blood cell count alone does not establish agranulocytosis. Conversely, the total white blood cell count may be misleading if other white blood cell populations remain relatively preserved.

Causes and mechanisms

Agranulocytosis develops through reduced neutrophil production in the bone marrow, accelerated destruction of neutrophils, or a combination of these processes.

Medication-associated agranulocytosis

Medications are an important cause of acquired agranulocytosis. Two broad patterns are distinguished:

  • Predictable marrow suppression: Cytotoxic chemotherapy can damage rapidly dividing marrow precursors. Neutrophil depletion commonly occurs alongside reductions in other blood-cell populations.
  • Idiosyncratic reactions: Some medicines cause severe neutrophil depletion in a small, susceptible subset of exposed people. These reactions may involve immune mechanisms or toxic effects on neutrophils and their precursors and are not explained simply by the medicine's usual dose-dependent effects.

Established examples of medicines associated with agranulocytosis include clozapine, antithyroid medicines such as methimazole and propylthiouracil, sulfasalazine, and certain antibiotics. The risk, timing, and mechanism differ between medicines. In some immune-mediated reactions, renewed exposure can produce a more rapid recurrence.

Other causes

Profound neutropenia can also occur with:

Nutritional deficiencies, including deficiencies of vitamin B12, folate, or copper, can cause neutropenia, although isolated, abrupt agranulocytosis is less characteristic.

The term is often used specifically for acute, acquired, medication-associated disease, while inherited and chronic disorders are usually described by their particular diagnoses.

Clinical features

Agranulocytosis may initially cause no symptoms and be detected through blood testing. When symptoms occur, they commonly reflect infection rather than the low neutrophil count itself.

Typical manifestations include fever, sore throat, painful mouth ulcers, gum inflammation, and difficulty swallowing. Infections may involve the lungs, skin, bloodstream, or tissues around the anus. Pneumonia and bloodstream infection can progress rapidly.

Because neutrophils contribute to pus formation and local inflammatory responses, familiar signs of infection may be reduced or absent. An infected site may produce little pus despite substantial tissue damage.

Infection risk depends not only on the lowest neutrophil count but also on the duration of depletion, the integrity of skin and mucosal barriers, accompanying immune dysfunction, and underlying illness.

Diagnosis and assessment

Diagnosis rests on a complete blood count with differential and confirmation of the ANC. A peripheral blood smear helps assess blood-cell appearance and identify abnormalities suggesting another blood disorder.

Assessment typically includes a detailed medication and medical history, with attention to recent treatment changes, previous blood counts, infections, and systemic disease. The timing of drug exposure is important, but a temporal association alone does not prove causation.

Additional investigations depend on the clinical setting:

  • Blood cultures and site-specific testing help identify infection.
  • Biochemical and nutritional tests may reveal contributing disorders.
  • Bone marrow examination, sometimes including biopsy, can distinguish impaired production from other mechanisms and investigate suspected marrow disease.

Drug-dependent neutrophil antibody testing is available in specialized settings, but technical limitations mean that a negative result does not exclude a drug-related mechanism. Re-exposure solely to establish causation is generally avoided because recurrence can be severe.

Clinical management

Management addresses both the cause of neutrophil depletion and its infectious complications. In suspected drug-induced agranulocytosis, withdrawal of the implicated medicine is a central component of care.

Fever accompanying profound neutropenia is treated as a medical emergency. Hospital-based management commonly includes prompt empirical broad-spectrum antibiotics, microbiological investigation, and supportive care. Antifungal treatment may be used in selected patients with persistent fever or evidence of fungal infection.

Granulocyte colony-stimulating factor (G-CSF) stimulates neutrophil production and is used in selected cases. It can shorten neutropenia in some settings, although evidence for its effect on mortality in non-chemotherapy drug-induced agranulocytosis is less definitive and varies with the population studied.

Treatment of congenital neutropenia, autoimmune disease, or marrow failure follows the underlying disorder rather than a uniform agranulocytosis protocol.

Prognosis and medication safety

Recovery depends on the cause and the marrow's capacity to resume neutrophil production. In reversible drug-induced cases, counts often recover over days to several weeks after the causative medicine is stopped. Recovery can be slower when marrow precursors are severely depleted or another marrow disorder is present.

Adverse outcomes are associated with profound or prolonged neutropenia, older age, substantial accompanying illness, and established severe infection. Modern antimicrobial and supportive treatment has improved outcomes, but agranulocytosis remains potentially fatal.

Blood-count monitoring is used with some medicines known to cause severe neutropenia. Requirements differ by medicine and jurisdiction, and monitoring cannot prevent every abrupt episode. Documentation and reporting of suspected reactions contribute to pharmacovigilance and help reduce inadvertent re-exposure.